This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.
Immune-Mediated Inflammatory Diseases (IMIDs) present an increasingly significant burden to patients, providers, and payors.
As Health Systems look for new ways to elevate care for patients, UCB strives to improve the patient’s clinical journey and works to support the evolution to high-quality, value-based care.
Resources and Quality Measures
Why You Should Identify axSpA Patients Early
Minimize the diagnostic delay for patients at risk for axSpA
A Value-Based Collaborative Care Model by Payers, Providers, and Pharma
Learn about building a model that prioritizes a holistic view of the patient, promotes communication among all those caring for the patient, and proactively confronts common barriers in the way of best practice protocols.